| Literature DB >> 35705262 |
Jemma Haines1,2,3, Jacklyn Ann Smith4,2, James Wingfield-Digby4, Jenny King4, Janelle Yorke5, Stephen J Fowler4,2,3.
Abstract
INTRODUCTION: Inducible laryngeal obstruction (ILO) describes transient laryngeal closure during respiration and can cause significant morbidity. Non-pharmacological behavioural therapy is the commonly cited treatment but efficacy is largely unknown. AIM: To synthesise the current evidence base on the effectiveness of non-pharmacological interventions used to treat adults with ILO.Entities:
Keywords: asthma; not applicable
Mesh:
Year: 2022 PMID: 35705262 PMCID: PMC9204450 DOI: 10.1136/bmjresp-2022-001199
Source DB: PubMed Journal: BMJ Open Respir Res ISSN: 2052-4439
Figure 1Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 flow diagram showing the screening and eligibility process using inclusion/exclusion criteria
Figure 2Components of interventions of included studies
Effect direction plot summarising direction of outcome domains of included studies
| Study | Study design | Symptoms (validated) | Symptoms (non-validated) | Objective measures | Healthcare utilisation |
| Hatzelis | CS | ▲ | ▲ | ||
| Nacci | O/U | ▲ | |||
| Pinho | CS | ▲ | |||
| Baxter | O/U | ▼ | ◄► | ▲ | |
| Haines | O/U | ▲ | |||
| Halevi-Katz, | O/U | ▲ | ◄► | ||
| Krammer | O/C | ▲ | ▲ | ||
| Marcinow | O/U | ▲ | |||
| Mathers-Schmidt & Brilla, 2005 | CS | ▲ | ◄► | ||
| Murry | O/U | ◄► | ▲ | ▲ | |
| Olley | O/U | ▲ | ▲ | ||
| Pargeter & Mansur, 2016 | O/U | ▲ | ▲ | ||
| Shin | O/U | ◄► | |||
| Warnes | CS | ▲ | ▲ |
Study design: O/U observational non-randomised uncontrolled before and after; O/C observational non-randomised controlled before and after; CS case study.
Effect direction: upward arrow ▲=positive impact; downward arrow ▼=negative impact; sideways arrow ◄►=no change/mixed effects/conflicting findings.
Sample size: final sample size (individuals) in intervention group. Large arrow ▲>300; medium arrow ▲ 50–300; small arrow ▲<50.
Study quality: denoted by row colour and JBI ratings assigned: green=low risk of bias; amber=some concerns; red=high risk of bias.
Symptom score outcomes of included studies pre–post completed intervention
| Validated scales | ||||||
| Study | N* | Validated symptom scale | Time point pre–post data collected | Premean/median† (SD/range) | Post mean/median† (SD/range) | P value |
| Baxter et al, 2019 | 35 | ACQ | 12 months | 2.50 (1.32) | 2.05 (1.14) | 0.19 |
| ACT | 12 months | 13.21 (4.73) | 14.69 (4.94) | 0.28 | ||
| Haines et al, | 16 | VCDQ | NR | 46† (20–60) | 38† (12–50)§ | 0.017 |
| Halevi-Katz, | 12 | DI | 3 weeks | 2.00 (5.39) | 16.83 (3.31)§ | 0.0016 |
| Murry et al, | 12¶ | RSI-7 | NR | NR | NR | 0.05** |
| Olley et al, 2013 | 4 | D12 | NR | 18.6 (7.8) | 6.3 (5.7) | NR |
|
| ||||||
|
| ||||||
|
|
|
|
|
| ||
| Krammer et al, 2017 | 25 | NR | 92 | NR | ||
| Marcinow et al, 2015 | 34 | NR | 100 (>2 sessions) 29 (1 session) | NR | ||
| Murry et al, | 16 | NR | NR (asked separately for cough, throat clear and hoarseness) | <0.01 | ||
|
| ||||||
|
|
|
|
|
| ||
| Hatzelis et al, 2012 | 1 | 12 months | Severity of symptoms; 1–5 | 5 | 1 | NR |
| Mathers-Schmidt and Brilla, 2005 | 1 | 16 weeks | Dyspnoea rating scale; 1–3 | 2.4 | 1.3 | NR |
| Nacci et al, 2011 ‡ | 10 | 24 months (received three intervention cycles) | Severity of symptoms; 1–10 | 9.2 | 6.2 | p<0.01 |
| 10 | 24 months (received eight intervention cycles) | 9.3 | 2.5 | p<0.01 | ||
| Warnes et al, 2005 | 1 | NR | Severity adaptive functioning; 1–6 | 5 | 0 | NR |
|
| ||||||
|
|
|
|
|
| ||
| Mathers-Schmidt and Brilla, 2005 | 1 | 16 weeks | Time to symptom onset | 23 s | 30 s | NR |
| Pargeter & Mansur, 2016 | 249 | NR | Frequency of patient reported daily attacks | 72% | 10% | NR |
|
| ||||||
|
|
|
|
|
| ||
| Pargeter & Mansur, | 249 | NR | In-house ILO symptom questionnaire; high score indicating poor control | 16.57 (3.96) | 7.75 (4.82) | <0.001 |
|
| ||||||
|
|
|
|
|
| ||
| Shin et al, 2018 | 46 | NR | Have symptoms a) not improved b) improved c) worsened | NA | 50% improve 22% worsen | NR |
*Number of participants.
†Median.
‡Studies reported statistically significant improvements pre–post intervention.
§Improved by the reported clinically meaningful response reported DI Dyspnoea Index Questionnaire; RSI Reflux Symptom Index item 7.
¶Only reported in 12/16 participants.
**Mean difference in score 3.76, no pre–post scores reported; D12 Dysponea12.
††Highest value most impairment.
ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test; NR, Not reported; VCDQ, Vocal Cord Dysfunction Questionnaire.
Healthcare utilisation of included studies pre–post completed intervention
| Study | N* | Healthcare utilisation measure | Time pre–post (months) | Pre mean (SD) | Post mean (SD) | P value | % change | Overall (mean) % change |
| Baxter | 35 | General practice visits | 12 | 10.17 (9.09) | 5.26 (5.36) | <0.001 | − 48% | |
| Baxter | 35 | Hospital admissions | 12 | 4.20 (4.66) | 2.40 (5.33) | 0.001 | − 43% | |
| Krammer | 25 | Asthma medication score | 6 | 4.6 | 1.92 | NR | − 58% | |
| Pargeter and Mansur, 2016 | 249 | Hospital admissions | 12 | 2.44 (4.84) | 0.31 (1.01) | <0.001 | − 87% | |
|
| 344 | − 59.5% |
*Number of participants.
NR, not reported.